- Home
- CANF vs BGMS Comparison
CANF vs BGMS Comparison
Compare CANF & BGMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CANF | BGMS |
|---|---|---|
| Founded | 1994 | 1996 |
| Country | Israel | Malaysia |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4M | 6.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CANF | BGMS |
|---|---|---|
| Price | $4.11 | $1.00 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $9,750.00 | N/A |
| AVG Volume (30 Days) | ★ 74.6K | 32.2K |
| Earning Date | 03-26-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $560,000.00 | $81,000.00 |
| Revenue This Year | $461.72 | $137.21 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 9.46 |
| 52 Week Low | $3.36 | $1.04 |
| 52 Week High | $46.60 | $100.75 |
Technical Indicators
Market Signals| Indicator | CANF | BGMS |
|---|---|---|
| Relative Strength Index (RSI) | 64.56 | 28.76 |
| Support Level | $4.00 | $1.28 |
| Resistance Level | $4.32 | $1.36 |
| Average True Range (ATR) | 0.29 | 0.11 |
| MACD | -0.16 | -0.03 |
| Stochastic Oscillator | 31.61 | 4.17 |
Price Performance
Historical ComparisonAbout CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.
About BGMS Bio Green Med Solution Inc.
Bio Green Med Solution Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib. The company derives its revenue from United Kingdoms.